Reuters logo
BRIEF-Zosano Pharma announces last subject treated in its migraine pivotal trial
January 5, 2017 / 2:09 PM / 10 months ago

BRIEF-Zosano Pharma announces last subject treated in its migraine pivotal trial

Jan 5 (Reuters) - Zosano Pharma Corp

* Zosano Pharma announces last subject treated in its migraine pivotal trial

* FDA indicated single, positive,pivotal efficacy study, in addition to safety study,to be sufficient for approval under 505(B)(2) pathway

* Company intends to conduct safety study after completion of Zotrip trial Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below